Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Finance

French biotech Deinove in receivership

by Alex Scott
November 13, 2022 | A version of this story appeared in Volume 100, Issue 40

 

Debt-laden French biotech start-up Deinove has begun proceedings to place it into financial receivership—a step toward disbanding. Deinove has 6 weeks from November before the commercial court of Montpellier, France, will determine whether new investors can be brought in and Deinove’s debts paid or if the company is to close. Trading of its shares on the Paris Euronext stock market were suspended on Oct. 28. Deinove has been developing biofuels, carotenoids, and antibiotics from Deinococcus bacteria.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.